Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site. # uBriGene ## Sitemaps - [XML Sitemap](https://www.ubrigene.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Exploring circRNA Therapy](https://www.ubrigene.com/exploring-circrna-therapy/) - Exploring the Benefits and Challenges of circRNA Therapy - [Analytical Methods and Testing for iPSC](https://www.ubrigene.com/analytical-methods-and-testing-for-ipsc/) - Review of Analytical Methods and Testing for iPSC Product Characterization - [QC for iPSC-derived therapy](https://www.ubrigene.com/qc-for-ipsc-derived-therapy/) - Quality Control Strategies for iPSC-Derived Therapies - [circRNA versus RNA therapy](https://www.ubrigene.com/circrna-versus-rna-therapy/) - The Dawn of the RNA Medicine Era Can circRNA Surpass Its Predecessors - [AAV in Gene therapy](https://www.ubrigene.com/aav-in-gene-therapy/) - Adeno-associated viruses: Challenges in Gene Therapy Commercialization ## Pages - [Home](https://www.ubrigene.com/) - [Webinars](https://www.ubrigene.com/webinars/) - [TIL](https://www.ubrigene.com/cdmo-services/gmp-cell-therapy/til/) - [Test password page](https://www.ubrigene.com/test-password-page/) - [Promotions](https://www.ubrigene.com/promotions/) - [iPSC Reprogramming Cocktail](https://www.ubrigene.com/ipsc-products/ipsc-reprogramming-cocktail/) - [Storage & Stability Study](https://www.ubrigene.com/analytical-assay-development/storage-and-stability-study/) - [Viral Vector Analytical Development Services](https://www.ubrigene.com/analytical-assay-development/viral-vector/) - [Plasmid & mRNA](https://www.ubrigene.com/analytical-assay-development/plasmid-and-mrna/) - [RNA-LNP Development and Synthesis](https://www.ubrigene.com/cro-services/custom-rna-synthesis/) - [sgRNA IVT Production](https://www.ubrigene.com/cro-services/sgrna-production/) - [Adenovirus Packaging](https://www.ubrigene.com/cro-services/viral-vector-manufacturing/adenovirus-packaging-service/) - [Lentivirus Packaging](https://www.ubrigene.com/cro-services/viral-vector-manufacturing/lentivirus-packaging-service/) - [AAV Packaging](https://www.ubrigene.com/cro-services/viral-vector-manufacturing/aav-packaging-service/) - [Plasmid Development and Production](https://www.ubrigene.com/cro-services/plasmid-production/) - [Regulatory Affairs Services](https://www.ubrigene.com/cdmo-services/regulatory-affairs-consulting/) - [Aseptic Fill and Finish](https://www.ubrigene.com/cdmo-services/sterile-fill-finish/) - [GMP Oncolytic Virus](https://www.ubrigene.com/cdmo-services/gmp-oncolytic-virus-manufacturing/) - [GMP Cell Banking](https://www.ubrigene.com/cdmo-services/gmp-cell-banking/) - [GMP Plasmid](https://www.ubrigene.com/cdmo-services/gmp-plasmid-manufacturing/) - [GMP AAV](https://www.ubrigene.com/cdmo-services/aav-gmp-manufacturing/) - [GMP saRNA-LNP](https://www.ubrigene.com/cdmo-services/gmp-rna-manufacturing/sarna/) - [GMP circRNA-LNP](https://www.ubrigene.com/cdmo-services/gmp-rna-manufacturing/circrna/) - [GMP mRNA-LNP](https://www.ubrigene.com/cdmo-services/gmp-rna-manufacturing/mrna/) - [GMP sgRNA IVT](https://www.ubrigene.com/cdmo-services/gmp-cell-therapy/sgrna-ivt/) - [GMP Lentivirus](https://www.ubrigene.com/cdmo-services/gmp-lentivirus-manufacturing/) - [iPSC & MSC](https://www.ubrigene.com/cdmo-services/gmp-cell-therapy/ipsc-msc-manufacturing/) - [CAR-T & CAR-NK](https://www.ubrigene.com/cdmo-services/gmp-cell-therapy/car-nk-car-t/) - [Cell Therapy](https://www.ubrigene.com/analytical-assay-development/cell-therapy/) - [Career](https://www.ubrigene.com/careers/) - [iPSC Banks](https://www.ubrigene.com/ipsc-products/ipsc-banks/) - [Ubrinuclease](https://www.ubrigene.com/ubrinuclease_pan_endonuclease/) - [Privacy Policy](https://www.ubrigene.com/privacy-policy/) - [Viral Vector Development and Production](https://www.ubrigene.com/cro-services/viral-vector-manufacturing/) - [News & Events](https://www.ubrigene.com/news/) - [QA & Regulatory Compliance](https://www.ubrigene.com/quality-and-regulatory/) - [Request a Quote](https://www.ubrigene.com/request-a-quote/) - [Contact Us](https://www.ubrigene.com/contact-us/) - [Facilities and Technology](https://www.ubrigene.com/facilities-and-technology/) - [Team](https://www.ubrigene.com/team/) - [About Us](https://www.ubrigene.com/about-us/) - [Case Studies](https://www.ubrigene.com/case-studies/) - [Brochures](https://www.ubrigene.com/brochures/) - [Blog](https://www.ubrigene.com/blog/) - [Gene Editing Products](https://www.ubrigene.com/gene-editing-products/) - [iPSC Products](https://www.ubrigene.com/ipsc-products/) - [Lentivirus Products](https://www.ubrigene.com/lentivirus-products/) - [AAV Products](https://www.ubrigene.com/aav-products/) - [GMP Lentivirus Packaging Plasmids](https://www.ubrigene.com/gmp-plasmid-products/lentivirus-plasmids/) - [GMP AAV Plasmids](https://www.ubrigene.com/gmp-plasmid-products/aav-plasmids/) - [Plasmid Products](https://www.ubrigene.com/gmp-plasmid-products/) - [Analytical Development & Testing](https://www.ubrigene.com/analytical-assay-development/) - [CRO Services](https://www.ubrigene.com/cro-services/) - [GMP Cell Therapy](https://www.ubrigene.com/cdmo-services/gmp-cell-therapy/) - [GMP RNA-LNP](https://www.ubrigene.com/cdmo-services/gmp-rna-manufacturing/) - [CDMO Services](https://www.ubrigene.com/cdmo-services/) - [Resources](https://www.ubrigene.com/resources/) - [Category Template](https://www.ubrigene.com/category-template/) - [Product Page](https://www.ubrigene.com/product-page/) - [Service Template](https://www.ubrigene.com/service-template/) ## Case Studies - [Successful Scale-Up of Oncolytic Virus Production for Clinical Trials](https://www.ubrigene.com/case-study/successful-scale-up-of-oncolytic-virus-production-for-clinical-trials/) - Summary Oncolytic virus therapy is a promising advancement in cancer immunotherapy, with four products approved globally, though production and quality control challenges remain. uBriGene's GMP production platform addresses these issues, providing scalable, cost-effective solutions and supporting an early-stage biotech company in advancing their Vaccinia Virus (VV) project through key stages, including process development, scale-up, and ## News & Events - [uBriGene At Advanced Therapies Week 2026 | CGT Innovation](https://www.ubrigene.com/news-events/ubrigene-at-advanced-therapies-week-2026-cgt-innovation/) - uBriGene to Drive Innovation in Cell & Gene Therapy at Advanced Therapies Week 2026 in San Diego - [uBriGene at JPM 2026 | Cell & Gene Therapy Innovation](https://www.ubrigene.com/news-events/ubrigene-at-jpm-2026-cell-gene-therapy-innovation/) - Where Science Meets Strategy: uBriGene Engages Global Leaders at JPM Healthcare Conference 2026 - [LVV Turbo™: uBriGene’s New GMP Lentiviral Vector Platform with UltraCell™ Integration](https://www.ubrigene.com/news-events/lvv-turbo-ubrigenes-new-gmp-lentiviral-vector-platform-with-ultracell-integration/) - uBriGene Launches LVV Turbo™ – Its Next-Generation GMP Lentiviral Vector Manufacturing Platform – and announces a Strategic Partnership with Syenex for integration of its UltraCell™ Technology - [uBriGene v2 RNA-LNP iPSC Kit PBMCs](https://www.ubrigene.com/news-events/ubrigene-v2-rna-lnp-ipsc-kit-pbmcs/) - uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - [uBriGene–Circurna Partnership Accelerates Circular RNA/LNP Therapeutics](https://www.ubrigene.com/news-events/ubrigene-circurna-partnership-accelerates-circular-rna-lnp-therapeutics/) - uBriGene Biosciences and Circurna Announce Strategic Partnership to Accelerate Development and Manufacturing of Circular RNA/LNP Therapeutics - [Advancing Lentiviral Vector Manufacturing at ASH 2025](https://www.ubrigene.com/news-events/ubrigenes-innovation-in-lentiviral-vector-production-at-67th-ash/) - uBriGene to Present High-Yield cGMP Lentiviral Vector Manufacturing Process at the 67th ASH Annual Meeting 2025 - [TIL Manufacturing Innovation at the 7th TIL Therapies Summit](https://www.ubrigene.com/news-events/til-manufacturing-innovation-at-the-7th-til-therapies-summit/) - uBriGene Biosciences to Showcase End-to-End TIL Manufacturing Innovation at the 7th TIL Therapies Summit in Boston, MA - [Connect with uBriGene at The Advanced Therapies USA 2025](https://www.ubrigene.com/news-events/connect-with-ubrigene-at-the-advanced-therapies-usa-2025/) - Meet uBriGene in Philadelphia: Driving the Future of Cell and Gene Therapy at The Advanced Therapies Congress 2025 - [Showcasing LVV Turbo at CAR-TCR Summit 2025](https://www.ubrigene.com/news-events/showcasing-lvv-turbo-at-car-tcr-summit-2025/) - From LVV Turbo to CAR-TCR Solutions: uBriGene to Showcase Innovation at CAR-TCR Summit 2025 in Boston - [Clinical iPSC Banks Released to Advance Cell Therapy](https://www.ubrigene.com/news-events/clinical-ipsc-banks-launched-to-accelerate-cell-therapy/) - uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development - [Pioneering CRISPR Breakthroughs Unveiled at Allogeneic Cell Summit 2025](https://www.ubrigene.com/news-events/ipsc-reprogramming-kit-to-debut-at-allogeneic-cell-summit/) - Novel sgRNA In Vitro Transcription (IVT) Technology Enhances Gene Editing Efficiency to Debut at the 7th Annual Allogeneic Cell Therapies Summit - [Driving Cell and Gene Therapy Innovation: uBriGene at ASGCT 2025](https://www.ubrigene.com/news-events/driving-cgt-innovation-ubrigene-at-asgct-2025/) - Integrated CDMO Solutions & Scientific Excellence at ASGCT 2025 - Booth 2149 - [Advancing iPSC Innovation at the ISSCR 2025](https://www.ubrigene.com/news-events/advancing-ipsc-innovation-on-the-global-stage/) - uBriGene Heads to ISSCR 2025: Advancing iPSC Innovation on the Global Stage - Booth 907 - [Drug Master File for iPSC Reprogramming mRNA-LNP Kit](https://www.ubrigene.com/news-events/ubrigene-submits-drug-master-file-for-ipsc-reprogramming-mrna-lnp-kit/) - Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology - [uBriGene's Breakthroughs at the 12th mRNA Health](https://www.ubrigene.com/news-events/ubrigenes-rna-breakthroughs-at-rna-health/) - Breakthrough RNA Therapies From uBriGene Featured at the 12th International mRNA Health Conference - [Educational Webinar Series by uBriGene](https://www.ubrigene.com/news-events/educational-webinar-series-by-ubrigene/) - uBriGene's Educational Webinar Series on ATMPs Development and Manufacturing - [Cell Therapy Potency Launching](https://www.ubrigene.com/news-events/cell-therapy-potency-launching/) - New Service Launch - Cell Therapy Potency Analytical Development and GMP Testing - [uBriGene's Showcase at ISCT 2024](https://www.ubrigene.com/news-events/ubrigenes-showcase-at-isct2024/) - uBriGene's showcase at ISCT2024 Vancouver May 29 - Jun 1 - [uBriGene Exhibits at ASGCT 2024](https://www.ubrigene.com/news-events/ubrigene-exhibits-at-asgct2024/) - uBriGene will exhibit at ASGCT2024 this May 7 – 11 in Baltimore - [Success Factors for Cell Therapy](https://www.ubrigene.com/news-events/success-factors-for-cell-therapy/) - Top 3 success factors for cell therapy potency assays - [Mustang Bio Transaction Completion](https://www.ubrigene.com/news-events/mustang-bio-transaction-completion/) - uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO) - [Targets North American Growth with Major Acquisition](https://www.ubrigene.com/news-events/targets-north-american-growth-with-major-acquisition/) - Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition - [20 Million USD Series C+ Round Closed](https://www.ubrigene.com/news-events/20-million-usd-series-c-round-closed/) - uBriGene Biosciences Inc. closes 150 million CNY (20 million USD) Series C+ round - [Completion of Series C Round Funding](https://www.ubrigene.com/news-events/completion-of-series-c-round-funding/) - uBriGene Biosciences completes several hundred million yuan Series C round funding - [IND Application Approval](https://www.ubrigene.com/news-events/ind-application-approval/) - Correcting visual impairment: VGR-R01 project IND application accepted by Center for Drug Evaluation - [uBriGene Highlights Research at Oncolytic Conference](https://www.ubrigene.com/news-events/ubrigene-highlights-research-at-oncolytic-conference/) - uBriGene Highlights Research at the 16th Oncolytic Virotherapy Conference, Rotterdam - [uBriGene at the 9th CAR-TCR Summit](https://www.ubrigene.com/news-events/ubrigene-at-the-9th-car-tcr-summit/) - Lunch & learn with uBriGene at the 9th CAR-TCR summit - [Clinical Application for Hemophilia B Accepted](https://www.ubrigene.com/news-events/clinical-application-for-hemophilia-b-accepted/) - Assisted Clinical Application of Gene Therapy for Hemophilia B of Vitalgen Accepted by NMPA - [Clinical Application in Ophthalmology Passed](https://www.ubrigene.com/news-events/clinical-application-in-ophthalmology-passed/) - Assisted Clinical Application of Gene Therapy in Ophthalmology of Innostellar Accepted by NMPA - [Discover uBriGene's Advancements at the Advanced Therapies 2024](https://www.ubrigene.com/news-events/discover-ubrigenes-advancements-at-the-advanced-therapies-congress-2024/) - Discover uBriGene’s Innovations at The Advanced Therapies Congress 2024! - [Delivering Innovation with Purpose: uBriGene at ISCT 2025](https://www.ubrigene.com/news-events/delivering-innovation-with-purpose-ubrigene-at-isct-2025/) - uBriGene to Present Real Solutions in Cell & Gene Therapy at ISCT 2025 - Booth 705 - [RNA Manufacturing Spotlight at World Vaccine Congress](https://www.ubrigene.com/news-events/rna-manufacturing-spotlight-at-world-vaccine-congress/) - uBriGene to Showcase RNA-LNP CRDMO Expertise at the 25th World Vaccine Congress Washington - [uBriGene to Showcase Innovations at ASH 2024](https://www.ubrigene.com/news-events/ubrigene-to-showcase-innovations-at-ash-2024/) - mRNA-LNP Mediated CAR-T Manufacturing from uBriGene Set to Shine at ASH 2024 - [Meet uBriGene at Meeting on the Mesa](https://www.ubrigene.com/news-events/ubrigene-engages-at-meeting-on-the-mesa/) - Meet uBriGene at the Cell & Gene Meeting on the Mesa 2024 - [Pioneering Gene Therapy: uBriGene as Your Strategic Partner](https://www.ubrigene.com/news-events/pioneering-gene-therapy-ubrigene-as-your-strategic-partner/) - uBriGene Biosciences Congratulates Strategic Partner InnoVec Biotherapeutics on FDA Clearance of IND for IVB103, An AAV-based Gene Therapy - [Meet uBriGene at BIO2024](https://www.ubrigene.com/news-events/meet-ubrigene-at-bio2024/) - Join uBriGene Biosciences to Discover the Future of Biotech at BIO San Diego Jun 03 - 06! ## Categories - [Uncategorized](https://www.ubrigene.com/category/uncategorized/) - [Brochure](https://www.ubrigene.com/category/brochure/) - [Webinar Slides](https://www.ubrigene.com/category/webinar-slides/) ## Categories - [News](https://www.ubrigene.com/news-event-categories/news/) - [Event](https://www.ubrigene.com/news-event-categories/event/) ## News-Events-Tags - [Corporate](https://www.ubrigene.com/news-events-tag/corporate/) - [Technology](https://www.ubrigene.com/news-events-tag/technology/)